Discussion on antiplatelet aggregation treatment options in high sensitive C-reactive protein less than 2 mg/L in patients with angina pectoris
10.11958/20160035
- VernacularTitle:超敏C反应蛋白小于2mg/L的心绞痛患者抗血小板聚集治疗方案探讨
- Author:
Wei YU
;
Fengyun ZHOU
;
Qing LIU
;
Sujuan ZHU
;
Xiaohua JIN
;
Peng LIU
- Publication Type:Journal Article
- Keywords:
hypersensitive C-reactive protein;
angina pectoris;
coronary artery disease;
antiplatelet aggregation therapy;
aspirin;
clopidogrel hydrogen sulfate
- From:
Tianjin Medical Journal
2016;44(8):967-969
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the feasibility of application of single and dual antiplatelet aggregation therapy in high sensitive C-reactive protein (hs-CRP) level in patients with angina pectoris. Methods Ninety-six hospitalized patients with angina 6~48 h (hs-CRP< 2 mg/L) were selected and randomly divided into single aspirin group (aspirin 100 mg/d, n=48) and aspirin plus clopidogrel combination therapy group (aspirin 100 mg/d and clopidogrel 75 mg/d, n=48). The efficacy was evaluated after 30-day treatment. Data of composite end points were analyzed by follow-up in patients within 6 months. Results The total effective rates were 85.42%for combination therapy group and 81.25%for single aspirin group. There was no significant difference in total effective rate between two groups (P>0.05). There were no significant differences in events of composite end points in patients after treatment between two groups (P > 0.05). Conclusion For angina pectoris patients with hs-CRP<2 mg/L, the risk of cardiovascular events is relatively little. There is no obvious difference in curative effect between single and dual antiplatelet aggreration therapies.
